Treatment of Masseteric Muscle Hypertrophy using a relaxing occlusal appliance and Botulinum Toxin Type A application: a case report
DOI:
https://doi.org/10.31984/oactiva.v6i1.534Keywords:
Hypertrophy, masseter muscle, Botulinum toxin, Bruxism, occlusal splintAbstract
Masseter hypertrophy is a benign condition which presents an enlargement of the masseter muscle that can occur unilaterally or bilaterally. Its etiology is unknown or idiopathic, although it is presumed to be caused by functional factors specific to everyone. The relaxing occlusal splint is considered a very frequent therapeutic indication in multiple pathologies or disorders of the cranio-cervicomandibular unit. This is the most used tool to treat temporomandibular disorders (TMD) and bruxism. Likewise, Botulinum Toxin Type A is a neurotoxin that in suitable amounts is used therapeutically or as a cosmetic product due to its ability to produce temporarily muscle paralysis, also being indicated in masseterine hypertrophy. The use of a relaxing occlusal splint and the application of botulinum toxin have been mostly studied separately, but the simultaneous use of these two therapeutic techniques could lead to an improvement in the results.
A 30 year old patient came into consult due to a unilateral masseteric hypertrophy of the right side, the treatment was the use of a relaxing occlusal splint during 24 hours complemented by injections of Botulinum Toxin type A, after a month of this application a noticeable improvement in facial aesthetics was observed, however after four months of the first application, a significant relapse was evident due to the drug’s half-life.
Downloads
References
González M, Miranda L, Malagón H, González V. Uso de toxina botulínica para tratamiento de la hipertrofia del músculo masetero. Cir Plast Iberolatinoam. 2012;38(3): 297-302.
Yanine N, Araya I, Cornejo M, Villanueva J. Tratamiento quirúrgico de hipertrofia maseterina: Reporte de un caso con seguimiento de seis años. Rev Esp Cirug Oral y Maxilofac. 2009;31(6): 381-384.
Xie Y, Zhou J, Li H, Cheng C, Herrler T, Li Q. Classification of Masseter Hypertrophy for Tailored Botulinum Toxin Type A Treatment. Plast Reconstr Surg. 2014;134(2):209e-218e.
Kim DH, Hong HS, Won SY, et al. Intramuscular nerve distribution of the masseter muscle as a basis for botulinum toxin injection. J Craniofac Surg. 2010;21:588–591.
Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115:919–930.
Kim NH, Chung JH, Park RH, Park JB. Botulinum Toxin Type A for the Treatment of Hypertrophy of the Masseter Muscle. Plast. Rec. Surg. 2010; 125 (6): 1693.
Young K, Taek S. The Change of Maximum Bite Force after Botulinum ToxinType A Injection for Treating Masseteric Hypertrophy. Plast. Rec. Surg. 2007; 120 (6):1662.
Santander H, Santander M, Valenzuela S y cols. Después de cien años de uso: ¿las férulas oclusales tienen algún efecto terapéutico?. Rev Clin Periodoncia Implantol Rehabil Oral. 2011;4(1):29-35.
Okeson J.P. Tratamiento de oclusión y afecciones temporomandibulares. Madrid: Elsevier; 2008.
Saavedra J, Balarezo J, Castillo D. Férulas Oclusales. Rev Estomatol Herediana. 2012;22(4): 242-246.
Espinar E, Alfonso MV, Chaqués J, Martín A, Solano E. Férulas oclusales como principio de obtención del diagnóstico en relación céntrica en ortodoncia. Manejo Clínico. Rev Esp Ortod. 2003;33: 41-49.
González M.C, Müller B. Estudio clínico de la Hipertrofia Maseterina - Revisión de la Literatura. Acta Odontológica Venezolana. 1998;36(2).
Lang A. History an uses of botox (Botulinum Toxin Type A). Lippincotts Case Manag. 2004;9: 109-112.22.
Castro W, Gomez R, da Silva Oliveira J, Moura M, Gomez R. Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg. 2005;63:20-4.
Tanaka E, Detamore M, Mercuri L. Degenerative disorders of the temporomandibular joint: etiology, diagnosis and treatment. J Dent Res. 2008;87(4): 296-307.
Moore A, Wood G. The medical management of masseteric hypertrophy with botulinum toxine type A. Br J Oral Maxillofac Surg. 1994;32: 26-28.
Rončevič, R. Masseter Muscle Hypertrophy Aetiology and Therapy. J Max-Fac Surg. 1986;14: 344-348.
Baş B, Özan B, Muğlalı M, Çelebi N. Treatment of maseteric hypertrophy with botulinum toxin: A report of two cases. Med Oral Patol Oral Cir Bucal. 2010;15(4): ce649-652.
Von Lindern J, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61(7):774-78.
Baker J, Nolan P. Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series. JADA. 2016;148(1):33-39.
Martínez-Pérez D. Toxina botulínica y su empleo en la patología oral y maxilofacial. Rev Esp Cirug Oral y Maxilofac. 2004; 26(3):149-154.
Published
- Abstract 1734
- PDF (Español (España)) 1528
- HTML (Español (España)) 318
How to Cite
Issue
Section
License
Se autoriza la reproducción total y parcial, y la citación del material que aparece en la revista, siempre y cuando se indique de manera explícita: nombre de la revista, nombre del autor(es), año, volumen, número y páginas del artículo fuente. Las ideas y afirmaciones consignadas por los autores están bajo su responsabilidad y no interpretan necesariamente las opiniones y políticas del Consejo Editorial de la Revista OActiva ni de la Universidad Católica de Cuenca.
La Revista OActiva utiliza la Licencia Creative Commons de Reconocimeinto-NoComercial-CompartirIgual 4.0, que es la siguiente: CC BY-NC-SA 4.0 Internacional.
